Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 1, Issue 20

September 12 2017

In this Issue

STIMULUS REPORTS
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY AND IMMUNOTHERAPY
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
COMMENTARY

STIMULUS REPORTS

Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome

Yoko Yoshida,Masanori Matsumoto,Hideo Yagi,Ayami Isonishi,Kazuya Sakai,Masaki Hayakawa,Yuji Hori,Toshiyuki Sado,Hiroshi Kobayashi,Yoshihiro Fujimura

View Articletitled, Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome

Supplemental data

In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy

Seth J. Rotz,Nathan Luebbering,Bradley P. Dixon,Eleni Gavriilaki,Robert A. Brodsky,Christopher E. Dandoy,Sonata Jodele,Stella M. Davies

View Articletitled, In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy

Supplemental data

Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in sickle cell disease

Maritza A. Jimenez,Enrico M. Novelli,Gray D. Shaw,Prithu Sundd

View Articletitled, Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in sickle cell disease

Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease
Clinical Trials & Observations

Joshua J. Field,Elaine Majerus,Victor R. Gordeuk,Michel Gowhari,Carolyn Hoppe,Matthew M. Heeney,Maureen Achebe,Alex George,Hillary Chu,Brian Sheehan,Maneka Puligandla,Donna Neuberg,Gene Lin,Joel Linden,David G. Nathan

View Articletitled, Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease

Supplemental data

HEMATOPOIESIS AND STEM CELLS

Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions

Kasem Kulkeaw,Tomoko Inoue,Tadafumi Iino,Kenzaburo Tani,Koichi Akashi,Nancy A. Speck,Yoichi Nakanishi,Daisuke Sugiyama

View Articletitled, Twist1 regulates embryonic hematopoietic differentiation through binding to <em>Myb</em> and <em>Gata2</em> promoter regions

Supplemental data

RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells

Takahiro Suzuki,Yuri Shimizu,Erina Furuhata,Shiori Maeda,Mami Kishima,Hajime Nishimura,Saaya Enomoto,Yoshihide Hayashizaki,Harukazu Suzuki

View Articletitled, RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells

Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets

Anne Zufferey,Edwin R. Speck,Kellie R. Machlus,Rukhsana Aslam,Li Guo,Mark J. McVey,Michael Kim,Rick Kapur,Eric Boilard,Joseph E. Italiano, Jr,John W. Semple

View Articletitled, Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets

Supplemental data

LYMPHOID NEOPLASIA

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

Kathryn G. Roberts,Yung-Li Yang,Debbie Payne-Turner,Wenwei Lin,Jacob K. Files,Kirsten Dickerson,Zhaohui Gu,Jack Taunton,Laura J. Janke,Taosheng Chen,Mignon L. Loh,Stephen P. Hunger,Charles G. Mullighan

View Articletitled, Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

Supplemental data

Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex
Clinical Trials & Observations

Alyssa I. Clay-Gilmour,Theresa Hahn,Leah M. Preus,Kenan Onel,Andrew Skol,Eric Hungate,Qianqian Zhu,Christopher A. Haiman,Daniel O. Stram,Loreall Pooler,Xin Sheng,Li Yan,Qian Liu,Qiang Hu,Song Liu,Sebastiano Battaglia,Xiaochun Zhu,AnneMarie W. Block,Sheila N. J. Sait,Ezgi Karaesmen,Abbas Rizvi,Daniel J. Weisdorf,Christine B. Ambrosone,David Tritchler,Eva Ellinghaus,David Ellinghaus,Martin Stanulla,Jacqueline Clavel,Laurent Orsi,Stephen Spellman,Marcelo C. Pasquini,Philip L. McCarthy,Lara E. Sucheston-Campbell

View Articletitled, Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex

Supplemental data

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Clinical Trials & Observations

Tracy E. Wiczer,Lauren B. Levine,Jessica Brumbaugh,Jessica Coggins,Qiuhong Zhao,Amy S. Ruppert,Kerry Rogers,Anli McCoy,Luay Mousa,Avirup Guha,Nyla A. Heerema,Kami Maddocks,Beth Christian,Leslie A. Andritsos,Samantha Jaglowski,Steven Devine,Robert Baiocchi,Jennifer Woyach,Jeffrey Jones,Michael Grever,Kristie A. Blum,John C. Byrd,Farrukh T. Awan

View Articletitled, Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib

Supplemental data

Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways

Sheryl M. Gough,Liat Goldberg,Marbin Pineda,Robert L. Walker,Yuelin J. Zhu,Sven Bilke,Yang Jo Chung,Joseph Dufraine,Subhadip Kundu,Elad Jacoby,Terry J. Fry,Susanna Fischer,Renate Panzer-Grümayer,Paul S. Meltzer,Peter D. Aplan

View Articletitled, Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways

Supplemental data

Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia

Xavier Cahu,Julien Calvo,Sandrine Poglio,Nais Prade,Benoit Colsch,Marie-Laure Arcangeli,Thierry Leblanc,Arnaud Petit,Frederic Baleydier,Andre Baruchel,Judith Landman-Parker,Christophe Junot,Jerome Larghero,Paola Ballerini,Eric Delabesse,Benjamin Uzan,Francoise Pflumio

View Articletitled, Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia

Supplemental data

MYELOID NEOPLASIA

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT

Akil A. Merchant,Aparna Jorapur,Amy McManus,Ren Liu,Valery Krasnoperov,Parvesh Chaudhry,Mohan Singh,Lisa Harton,Mary Agajanian,Miriam Kim,Timothy J. Triche, Jr,Brian J. Druker,Jeffrey W. Tyner,Parkash S. Gill

View Articletitled, EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT

Supplemental data

Loss of mDia1 causes neutropenia via attenuated CD11b endocytosis and increased neutrophil adhesion to the endothelium

Yang Mei,Gong Feng,Nina Rahimi,Baobing Zhao,Jingxin Zhang,Lan Cao,Jing Yang,Juehua Gao,Yihua Chen,Ronen Sumagin,William A. Muller,Ling Zhang,Peng Ji

View Articletitled, Loss of mDia1 causes neutropenia via attenuated CD11b endocytosis and increased neutrophil adhesion to the endothelium

Supplemental data

Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBPα to prevent Trib1-driven acute myeloid leukemia

Ikuko Nakamae,Jun-ya Kato,Takashi Yokoyama,Hidenori Ito,Noriko Yoneda-Kato

View Articletitled, Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBPα to prevent Trib1-driven acute myeloid leukemia

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
Clinical Trials & Observations

Jay Y. Spiegel,Caroline McNamara,James A. Kennedy,Tony Panzarella,Andrea Arruda,Tracy Stockley,Mahadeo Sukhai,Mariam Thomas,Justyna Bartoszko,Jenny Ho,Nancy Siddiq,Dawn Maze,Aaron Schimmer,Andre Schuh,Hassan Sibai,Karen Yee,Jamie Claudio,Rebecca Devlin,Mark D. Minden,Suzanne Kamel-Reid,Vikas Gupta

View Articletitled, Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

Supplemental data

COMMENTARY

Neurologic event–free survival demonstrates a benefit for SCID patients diagnosed by newborn screening
Clinical Trials & Observations

Christopher C. Dvorak,Jennifer M. Puck,Justin T. Wahlstrom,Morna Dorsey,Alexis Melton,Morton J. Cowan

View Articletitled, Neurologic event–free survival demonstrates a benefit for SCID patients diagnosed by newborn screening

Cover Image

Cover Image

COVER FIGURE
Lack of inhibition of platelet-neutrophil aggregation in control peptide–treated sickle cell disease patient blood flowing through microfluidic flow channels presenting a combination of P-selectin, ICAM-1, and interleukin-8. Freely flowing platelets (round green objects) are shown nucleating on arrested neutrophils (pink). The image was recorded with quantitative microfluidic fluorescence microscopy. See the article by Jimenez et al, which demonstrates that a glycoprotein Ibα antagonist (CCP-224) prevents platelet-neutrophil aggregation in blood of patients with sickle cell disease.
Front Matter
Editorial Board

All Issues

Email alerts

Continuous Publishing Alert

New Journal Content Alert

Latest
Most Read
Most Cited

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.

Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon

A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia

Race and ethnicity reporting and representation in hemophilia clinical trials

Table of Contents

STIMULUS REPORTS

Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome

In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy

Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in sickle cell disease

CLINICAL TRIALS AND OBSERVATIONS

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease
Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions

RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Mature murine megakaryocytes present antigen-MHC class I molecules to T cells and transfer them to platelets

LYMPHOID NEOPLASIA

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex
Clinical Trials & Observations

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Clinical Trials & Observations

Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways

Bone marrow sites differently imprint dormancy and chemoresistance to T-cell acute lymphoblastic leukemia

MYELOID NEOPLASIA

EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT

Loss of mDia1 causes neutropenia via attenuated CD11b endocytosis and increased neutrophil adhesion to the endothelium

Myeloid leukemia factor 1 stabilizes tumor suppressor C/EBPα to prevent Trib1-driven acute myeloid leukemia

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
Clinical Trials & Observations

COMMENTARY

Neurologic event–free survival demonstrates a benefit for SCID patients diagnosed by newborn screening
Clinical Trials & Observations

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

STIMULUS REPORTS

CLINICAL TRIALS AND OBSERVATIONS

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex Clinical Trials & Observations

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib Clinical Trials & Observations

MYELOID NEOPLASIA

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy Clinical Trials & Observations

COMMENTARY

Neurologic event–free survival demonstrates a benefit for SCID patients diagnosed by newborn screening Clinical Trials & Observations

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease
Clinical Trials & Observations

Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex
Clinical Trials & Observations

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Clinical Trials & Observations

Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
Clinical Trials & Observations

Neurologic event–free survival demonstrates a benefit for SCID patients diagnosed by newborn screening
Clinical Trials & Observations